Personalized mutation tracking could spot relapse sooner in bone marrow cancer patients
NCT ID NCT02872662
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at 308 people with myelodysplastic syndromes (MDS) who had a stem cell transplant. Researchers identified each patient's unique genetic mutations and then monitored those mutations in blood and bone marrow samples after transplant. The goal was to see if rising mutation levels could signal a relapse before it becomes obvious, potentially allowing earlier treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could lead to a way to catch relapse earlier in MDS patients after transplant, potentially improving outcomes.
What could go wrong
This is an observational study, not a treatment trial. It may not change patient outcomes directly, and the methods may not be widely applicable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MDS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Hematology and Coagulation, Sahlgrenska University hospital
Gothenburg, 413 45, Sweden
-
Department of Hematology, Aarhus University Hospital
Aarhus, 8000, Denmark
-
Department of Hematology, Akademiska University Hospital
Uppsala, 751 85, Sweden
-
Department of Hematology, Karolinska University Hospital
Stockholm, Sweden
-
Department of Hematology, Lund University Hospital
Lund, 221 85, Sweden
-
Department of Hematology, Rigshospitalet Univsersity Hospital
Copenhagen, Denmark
-
Department of Hematology, Rikshospitalet University Hospital
Oslo, 0027, Norway
-
Department of Medcine, Haukeland University Hospital
Bergen, Norway